Epitalon (AEDG) is a synthetic tetrapeptide modeled on the bovine pineal extract epithalamin, developed by Khavinson's St. Petersburg group. It activates telomerase and extends telomeres ~33% in human cell lines, with 2025 work adding a second route via ALT; animal lifespan data is positive. Human data is limited to two small, single-site Russian trials, retinitis pigmentosa (n=162) and circadian measures (n=75), with no Western replication.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does Epitalon lengthen telomeres?
In cells, yes: it reactivates hTERT in telomerase-negative fibroblasts, elongated telomeres by a reported 33.3%, and 2025 work showed ALT-pathway activity too. Whether that translates to human longevity is unproven.334
Has Epitalon been tested in humans?
Two small Russian clinical signals: 162 retinitis pigmentosa patients with improved visual measures, and 75 women with increased melatonin-metabolite excretion versus placebo. No Western trial has replicated either.2
Is Epitalon legal in the US?
It is not FDA-approved and has no US IND; it was part of the 2026 PCAC compounding review, where the committee recommended it for the 503A list despite an FDA-flagged carcinogenicity concern. Gray-market counterfeits are a documented problem.
Is Epitalon safe?
Russian sources report 40+ years of clinical use without adverse effects and animal data shows anti-tumor rather than pro-tumor effects. But these are non-Western sources, and a PCAC member flagged carcinogenicity risk in deliberation.2
Aliases: Epithalon, Epithalone, Epithalamin (parent extract) Sequence: Ala-Glu-Asp-Gly (AEDG) — tetrapeptide Molecular Weight: ~390 Da (free base); salts commonly acetate or trifluoroacetate (TFA) Origin: Synthetic tetrapeptide based on amino acid composition of Epithalamin (bovine pineal gland extract). AEDG was confirmed in authentic pineal polypeptide complex solution in 2017 (Khavinson et al., PMID 29124531) — it is endogenous, not purely a drug invention.
02Overview
Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) synthesized by Vladimir Khavinson and his team at the St. Petersburg Institute of Bioregulation and Gerontology based on the amino acid composition of Epithalamin, a polypeptide extract from the bovine pineal gland. It is one of the most studied anti-aging peptides, with research spanning over 25 years since its 2001 Russian patent (referenced in PMC11943447). It occupies the unique position of being a Russian Federation peptide bioregulator (short regulatory peptide class).
Epitalon's most celebrated property is its ability to activate telomerase and elongate telomeres — the protective caps on chromosomes that shorten with each cell division. This positions it as a potential geroprotector at the most fundamental cellular level.
Evidence Level (as of Sept 2026): Moderate-to-strong preclinical; modest human evidence. Key 2025 mechanistic advance: dual mechanism confirmed — telomerase upregulation AND Alternative Lengthening of Telomeres (ALT) activation (Igarashi et al., Biogerontology 2025, PMID 40908429 / PMC12411320). Telomerase activity alone is now known to be insufficient in many human cell lines; ALT adds a parallel telomere-maintenance route.
03Mechanism of Action
Telomerase Activation & ALT (Updated 2025)
- Reactivates hTERT expression in telomerase-negative human fetal fibroblast cultures (Khavinson, Bondarev, Butyugov, 2003, PMID 12937682)
- Elongates telomeres by an average of 33.3% in human somatic cells
- 2025 update — ALT pathway also engaged: Igarashi S et al., Biogerontology 2025 Sep 4;26(5):178 (PMC12411320). Demonstrated Epitalon increases telomere length in human cell lines through either telomerase upregulation or Alternative Lengthening of Telomeres (ALT) activity, depending on baseline hTERT status. This is a mechanism-resolving finding: it explains how Epitalon can act on ALT-positive tumors as well as telomerase-reactivated somatic cells (and supports its reported anti-tumor profile).
- Control fibroblasts lost mitotic capacity after passage 34; Epitalon-treated cells continued past passage 44 (Khavinson, May 2004 Bull Exp Biol Med).
- Telomere repeat amplification protocol (TRAP) confirms telomerase induction in HeLa and 602/17 fetal fibroblasts.
Pineal Gland & Melatonin Axis
- Restores melatonin synthesis in aged pinealocytes by elevating AANAT and pCREB expression (more potent at 3h than Vilon; PMID 22816096, Khavinson 2012)
- In vivo in old rhesus monkeys (22.8 ± 1 yr): IM Epitalon normalized cortisol and stimulated melatonin synthesis in age-dependent manner (Goncharova et al.)
- In vitro conflict: Djeridane et al. 2003 (PMID 12809170) found no direct melatonin secretion effect in isolated perifused pineal glands from young/old rats — suggesting Epitalon acts on synthesis machinery rather than secretion per se
- Human circadian RCT signal: 75 women, 0.5 mg/day sublingual × 20 days → 1.6× urinary 6-sulfatoxymelatonin (aMT6s) vs placebo; Clock gene expression −1.8×, Cry2 +2×, Csnk1e −2.1× (p < 0.05). Mechanistic support for geroprotective activity via clock gene modulation.
Gene Regulation & DNA Binding
- Direct DNA binding confirmed (FITC-labeled Epitalon penetrates HeLa cells and reaches the nucleus; binds CAG-repeat sequences susceptible to cytosine methylation)
- In silico: binds ATTTG and ATTTC promoter sequences — the ATTTC motif is repeated multiple times in the telomerase gene promoter (Khavinson 2004)
- Epigenetic regulation: interacts with histone H1/3 and H1/6 (binding energies −56.49 and −64.51 kcal/mol; molecular dynamics AMBER12EHT) — first non-DNA epigenetic route
- Plant system validation: Nicotiana tabacum callus assays confirm Epitalon binds CAG regions of plant DNA
- Solovyev et al.: Epitalon reduces dsDNA melting temperature by up to 41 °C at 0.1 M NaCl ionic strength
Transporter Binding (New 2020 finding)
- In silico docking: strong binding to LAT1, LAT2, PEPT1, PEPT2 amino acid transporters (comparable to known PEPT1 inhibitors). Suggests anti-cancer mechanism via amino acid transport blockade — explains observed tumor-suppression without direct cytotoxicity.
Antioxidant & Nrf2
- Direct Keap1/Nrf2 promoter binding demonstrated (Gutop et al.) — upregulates SOD-1, NQO1, catalase expression
- In D. melanogaster, 16,000-fold lower concentration than melatonin achieves comparable lifespan extension — "signaling role" rather than stoichiometric antioxidant
Other Mechanisms
- STAT1 phosphorylation in THP-1 monocytic leukemia cells (receptor-independent; additive with LPS → ERK1/2 phosphorylation; suppresses STAT3)
- Cholinergic: +10–25% AChE/BuChE activity in SH-SY5Y (Nalieva et al.); −20% soluble APP secretion → potential AD-relevant modulation
- Anti-mutagenic in albino & grey mice (sperm head abnormalities, micronuclei in peripheral blood erythrocytes)
- Anti-apoptotic: 2.12-fold reduction in splenic lymphocyte apoptosis post-γ-irradiation (Kozina)
- Cytokine modulation: IL-2 mRNA elevation in splenocytes (5h vs 20h for Vilon); regioselective hypothalamic IL-2 mRNA changes after IM/intranasal
Anti-Tumor Effects
- HER-2/neu transgenic FVB/N mice: 3.7-fold lower HER-2/neu mRNA expression; reduced mammary adenocarcinoma count (p < 0.05)
- C3H/He mice: 6.5-month study — reduced tumor incidence, multiplicity, localization vs saline
- SAMP-1 mice (accelerated aging model): Epitalon reduced chromosomal abnormalities more than melatonin in SHR controls
- 1,2-dimethylhydrazine colon carcinogenesis model: significant decrease in cancer incidence
- Frailty-model dependent: Semenchenko et al. showed Epitalon either reduced max lifespan (debilitation/frailty accumulation) or enhanced survival (robustness/heterogeneity) depending on dose schedule — non-monotonic dose-response
04Evidence by Biological System ( PMC11943447 taxonomy)
| Model | Key Findings |
|---|---|
| Human cell lines | Telomere elongation (33.3%); Hayflick limit overcome; AChE/BuChE modulation; oocyte protection (DNA damage ↓, apoptosis ↓); 2025 bovine oocyte telomerase + JC-1 mito health improvement (Ullah Life Sci 2025) |
| D. melanogaster | ↑ Lifespan by up to 16% in both sexes (mature/old flies affected); antioxidant at 0.00001% w/w; better antioxidant than Epithalamin at 1000× lower dose |
| Mice (CBA, C3H/He, FVB/N, SAMP-1, SHR) | ↑ Lifespan (23-month mice reached 4× control rate; oldest Epitalon mouse 34 mo vs 24 mo control); ↓ chromosomal aberrations 17.1% (SHR); ↑ survival last 10% by 13.3% (SHR); anti-tumor across strains |
| Rats (Wistar, LIO, Campbell) | Pinealectomy gastric cell recovery (42 days); Campbell rats retinal functional activity +43.9% (parabulbar) and 2-fold (maternal IP); oral glucose transport ↑2.2–8× in proximal/medial small intestine; nephroprotective in glycerol/cisplatin AKI |
| Rhesus monkeys | Old monkeys: melatonin ↑, cortisol normalized; glucose response area ↓ in old (479.6 → 388.9 mM/min); ↑ in young (294.9 → 343.3) |
| Rabbits (Chinchilla) | Dansyl-labeled Epitalon integrates rapidly into maternal + fetal tissues under placental insufficiency |
| Clinical — Retinitis pigmentosa | n=162 patients, parabulbar 5 µg/eye × 10 days; visual acuity ↑ 0.15–0.20; visual field borders extended in 64.8% by 90–120°; no side effects |
| Clinical — Circadian | 75 women, 0.5 mg/day sublingual × 20 days; 1.6× aMT6s vs placebo |
| Plant (N. tabacum) | Callus proliferation ↑ at low doses (10⁻⁷ M); gene expression changes in CLE/GRF/KNOX families |
Swipe table →
052025 Mechanism Update: Dual Telomere Maintenance
The single most significant mechanistic advance for Epitalon in 2025 was the demonstration that Epitalon engages both the telomerase AND ALT pathways depending on the baseline hTERT status of the cell (Igarashi S et al., Biogerontology 2025 Sep 4;26(5):178, PMID 40908429 / PMC12411320). This:
- Resolves the long-standing puzzle of how a single tetrapeptide produces effects in ALT-positive (telomerase-negative) tumor cells as well as in telomerase-reactivated somatic cells.
- Confirms Epitalon has activity independent of canonical hTERT induction — broader applicability than previously assumed.
- Aligns with the documented anti-tumor profile (anti-cancer effect via amino acid transporter blockade is mechanistically independent of telomere status).
Companion 2025 finding (Ullah S et al., Life Sci 2025;362:123381, cited in Araj review): Epitalon enhanced bovine oocyte maturation and post-thawed embryo development via telomerase + mitochondrial pathways (PGC-1α, Sirt-1, tFAM, BCL2 ↑; JC-1 mito health ↑; intracellular ROS ↓). First evidence that Epitalon accelerates blastocyst expansion/hatching — relevant to reproductive longevity research.
06Doses in studies
⚠️ Disclaimer: Research protocols. Epitalon is not FDA-approved. Quality concerns: Vanhee et al. confirmed LC-MS/MS is the only reliable way to distinguish genuine AEDG from EADG (Glu-Ala-Asp-Gly) counterfeit, which arises via N-terminal glutamic acid pyroglutamate formation during heat treatment. Counterfeit risk is non-trivial in unregulated gray market.
Approaches Reported in the Literature
- Often combined with Thymogen (Glu-Trut dipeptide) for immune support or other pineal peptides
- Retinal protocol (per Russian clinical trial, St. Petersburg IBG): 5 µg/eye parabulbar × 10 days
07Safety Profile
| Aspect | Assessment |
|---|---|
| Overall safety | Excellent — no reported toxic, allergic, or adverse effects across 40+ years of Russian clinical use |
| Acute toxicity | None observed even at high doses in animal studies |
| Long-term safety | Used clinically in Russia since the 1990s |
| Cancer risk | Anti-tumor rather than pro-tumor — reduces tumor incidence in animal models across multiple strains |
| FDA status | Not approved in the United States; no IND/CTA in US; subject of 2026 PCAC compounding panel review (see FDA Peptide Reclassification 2026 — Regulatory Intelligence) |
| Russian clinical experience | n=162 retinitis pigmentosa patients; no side effects reported |
| Stability concern | Short peptide; rapid in vivo degradation. Authors of PMC11943447 recommend acetylation/amidation modification as future direction — not yet evaluated |
| Stereoisomer question | 8 possible stereoisomers; only L-amino acid form characterized. Other 7 unstudied |
| Counterfeit risk | Significant in gray market (EADG vs AEDG confusion, pyroglutamate formation); Vanhee LC-MS/MS is the gold standard |
Swipe table →
08Clinical Reality Check (Sept 2026)
- No FDA-approved indication anywhere outside Russia
- Clinical trial landscape: All published human data is Russian (St. Petersburg IBG, Goncharova lab). Two human signals: retinitis pigmentosa (n=162, parabulbar) and circadian (n=75 women, sublingual). Both small, single-site, no Western replication.
- Mechanism is now better understood thanks to 2025 Igarashi ALT paper + transporter docking
- Quality control is the active risk: LC-MS/MS confirmation per Vanhee et al.; the EADG counterfeit is indistinguishable by mass alone
- Stability is an unresolved pharmacokinetic challenge — no published acetylated/amidated analog studies
09Source & Origin
- Developer: Vladimir Khavinson (St. Petersburg Institute of Bioregulation and Gerontology)
- Parent compound: Epithalamin — polypeptide extract from bovine pineal gland (used in Russian clinical practice since 1990s)
- Synthesis: Short peptide (tetrapeptide) from amino acids based on Epithalamin's active sequence; patented 2001 in Russian Federation
- Endogenous confirmation: AEDG identified in physiological pineal polypeptide solution in 2017 (Khavinson, Kopylov et al., PMID 29124531)
- Part of: Khavinson's systematic approach to peptide bioregulation — see Khavinson Peptides (Russian Bioregulators)
10Where to get it
Epitalon is sold mainly through gray-market vendors whose products are not independently tested. We don't link to sellers of compounds like this, affiliate or otherwise. How we make money
11Connections
12Sources
- Khavinson VKh, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin'kova NS. (2017). Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bull Exp Biol Med 164:41–43. PMID 29124531 — endogenous confirmationPubMed 29124531
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci 26(6):2691. PMCID PMC11943447 / PMID 40141333 — comprehensive 25-year synthesis reviewPMC11943447 · PubMed 40141333
- Igarashi S et al. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 26(5):178. PMID 40908429 / PMC12411320 — ALT mechanism resolutionPubMed 40908429 · PMC12411320
- Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 135:590–2. PMID 12937682 — foundational human cell line resultPubMed 12937682
- PubMed 22816096PubMed 22816096
- Djeridane Y, Khavinson VK, Anisimov VN, Touitou Y. (2003). Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. J Endocrinol Investig 26:211–215. PMID 12809170 — null in vitro secretion resultPubMed 12809170
- Ullah S et al. (2025). Epitalon-activated telomerase enhances bovine oocyte maturation rate and post-thawed embryo development. Life Sci 362:123381. doi 10.1016/j.lfs.2025.123381 — reproductive longevity evidenceDOI 10.1016/j.lfs.2025.123381
- Khavinson VKh, Razumovsky MI, Trofimova SV, Grigorian R, Razumovskaya A. (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuroendocrinol Lett 23:365–368. PMID 12195242 — n=162 retinitis pigmentosa clinical trialPubMed 12195242
- Khavinson VKh et al. (2002). Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett 24:233–240. PMID 14523363PubMed 14523363
- Anisimov VN, Khavinson VK, Morozov VG. (1994). Twenty years of study on effects of pineal peptide preparation: Epithalamin in experimental gerontology and oncology. Ann N Y Acad Sci 31:483–493. PMID 8010617PubMed 8010617
- Khavinson VKh, Kuznik BI, Ryzhak GA. (2013). Peptide bioregulators: The new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol 26:20–37. PMID 24003726PubMed 24003726
13Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.